Prothena Corp Public (PRTA) Income from Continuing Operations (2012 - 2026)
Prothena Corp Public (PRTA) posted quarterly Income from Continuing Operations of 32721000.0 for Q1 2026, up 154.36% year-over-year from 12864135.14 in Q1 2025, and up 251.89% quarter-over-quarter from 21542000.0 in Q4 2025.
Prothena Corp Public (PRTA) Income from Continuing Operations (2012 - 2026) Analysis & Trends
Prothena Corp Public's Income from Continuing Operations history runs 15 years deep, the most recent figure standing at 32721000.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations rose 154.36% year-over-year to 32721000.0; the TTM figure through Mar 2026 stood at 151100000.0 (down 36.91% YoY), while the FY2025 annual figure was 244092000.0, down 99.57% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 32721000.0, up from 21542000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 66847000.0 in Q2 2024, with the low at 125767000.0 in Q2 2025.
- The 5-year median for Income from Continuing Operations is 45717000.0 (2022), against an average of 35157176.47.
- The sharpest annual moves came in 2023 and 2024: Income from Continuing Operations sank 1162.78% in 2023, then jumped 222.43% in 2024.
- Prothena Corp Public's Income from Continuing Operations stood at 6349000.0 in 2022, then tumbled by 1162.78% to 67476000.0 in 2023, then increased by 14.07% to 57981000.0 in 2024, then surged by 62.85% to 21542000.0 in 2025, then soared by 251.89% to 32721000.0 in 2026.
- Business Quant data shows PRTA's Income from Continuing Operations at 32721000.0 in Q1 2026, 21542000.0 in Q4 2025, and 36512000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,096.02 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Prothena Corp Public | 458.45 Mn | 170.25 Mn | - | -18.58 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -18.58 Mn |
| Mar 31, 2026 | 32.72 Mn |
| Dec 31, 2025 | -21.54 Mn |
| Sep 30, 2025 | -36.51 Mn |
| Jun 30, 2025 | -125.77 Mn |
| Mar 31, 2025 | -60.20 Mn |
| Dec 31, 2024 | -57.98 Mn |
| Sep 30, 2024 | -59.04 Mn |
| Jun 30, 2024 | 66.85 Mn |
| Mar 31, 2024 | -72.24 Mn |
| Dec 31, 2023 | -67.48 Mn |
| Sep 30, 2023 | 21.92 Mn |
| Jun 30, 2023 | -54.60 Mn |
| Mar 31, 2023 | -46.88 Mn |
| Dec 31, 2022 | 6.35 Mn |
| Sep 30, 2022 | -45.72 Mn |
| Jun 30, 2022 | -41.27 Mn |
| Mar 31, 2022 | -36.29 Mn |
| Dec 31, 2021 | -33.14 Mn |
| Sep 30, 2021 | 109.25 Mn |